A phase IV clinical trial of Licartin combined with radio-frequency ablation for prevention of hepatocellular carcinoma recurrence

A clinical study of antibody-targeted therapy of hepatocellular carcinoma

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001684

Enrollment

Unknown

Registered

2011-11-06

Start date

2011-09-30

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

A:Licartin with conventional RFA

B:Conventional RFA

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients are entirely voluntary, good compliance; sign the informed consent form; 2. Diagnosis of hepatocellular carcinoma by pathology; 3. ECOG score of physical state =3*10^9/L platelet counts >50*10^9/L; 7. Expected survival >=3 months; 8. No extrahepatic metastasis or vascular invasion.

Exclusion criteria

Exclusion criteria: 1. Allergic to biological agents, hypersensitiveness; 2. Pregnant or breast-feeding women; 3. The initial skin test-positive patients for metuximab antibody; 4. Patients with hypothyroidism.

Design outcomes

Primary

Measure	Time frame
1, 2, 3, 5-year survival rates;Overall survival;Recurrence time of residual lesions of primary tum;Recurrence time of distant lesions of primary tumor;3, 6, 12, 24-month recurrence rates;Time to tumor recurrence (TTR);	—

Countries

China

Contacts

Public ContactZhi-Nan Chen

znchen@fmmu.edu.cn+86 029 84773243

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026